search
Back to results

Migraine--Investigational Treatment of Migraine With Noninvasive Brain Stimulation. (tDCS- Migraine)

Primary Purpose

Migraine

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
DC Stimulator (Transcranial Direct Current Stimulator)
Sponsored by
Beth Israel Deaconess Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Migraine focused on measuring migraine, headache, chronic, pain, brain, neurology, stimulation, noninvasive, transcranial, direct, current, tDCS, tms, rTMS, BIDMC

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subjects must be between 18 and 65 years of age.
  • The diagnosis must meet the 2004 IHS criteria for migraine without aura, migraine with aura, or chronic migraine.
  • The duration of the disease must be of at least one year.
  • Subjects must have maintained their routine preventative medication consistently for at least two months (if applicable) prior to study initiation.

Exclusion Criteria:

  • Patients with major depression with suicidal risk, as clinically defined.
  • Patients with other known neuropsychiatric disorders.
  • Patients with other chronic pain disorders
  • History of substance abuse or dependence within the last six months
  • Known brain metastasis
  • History of neurological disorders (such as stroke)
  • History of brain surgery
  • Prior experience with tDCS
  • Abnormal neurological examination, other than those pertaining to the signs of the condition studied in this protocol.
  • Contraindication to tDCS: metallic hardware in the head or scalp: shrapnel, surgical clips, or fragments from welding

Sites / Locations

  • Beth Israel Deaconess Medical Center: Berenson-Allen Center for Noninvasive Brain Stimulation

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

No Intervention

Experimental

No Intervention

Other

Arm Label

Baseline- 1 month

tDCS- 1 month

Follow Up- 4 months

Active tDCS- 1 month

Arm Description

Subjects will be asked to maintain a migraine diary in which they will record the onset of each migraine, migraine-associated symptoms, migraine-associated pain, daily average pain, and daily average anxiety.

There will be 10- twenty minute sessions of the tDCS intervention over a four week period. During each tDCS session, two electrodes are placed over selected areas of the brain. 2 mA of direct current will flow through the electrodes, penetrate the scalp, and create a flow of electrical current in the brain. The subject may feel a slight itching on the scalp. The procedure will last 20 minutes. For sham tDCS, an alternate method of stimulation will be used. During this phase, participants will continue to maintain their migraine diary. In addition, the pain threshold of patients will be measured at the first, fifth, and tenth sessions via Thermal Sensory Analysis and Von Frey Hair tests.

During the follow up phase, subjects will meet with the study investigators a total of 5 times for follow up monitoring. Participants will continue to maintain their migraine diary during this time.

Participants randomized to sham tDCS (placebo) will be given the opportunity to receive the active intervention if the intervention is found to be safe and efficacious.

Outcomes

Primary Outcome Measures

Migraine-associated pain (maximum headache intensity)
Migraine frequency (# of headache days per month)
Daily average pain

Secondary Outcome Measures

Thermal pain threshold
Daily average anxiety
Analgesic drug use
Von Frey Hair

Full Information

First Posted
August 23, 2007
Last Updated
March 17, 2017
Sponsor
Beth Israel Deaconess Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT00521196
Brief Title
Migraine--Investigational Treatment of Migraine With Noninvasive Brain Stimulation. (tDCS- Migraine)
Official Title
Phase 2 Study of the Effect of Transcranial Direct Current Stimulation (tDCS) on Pain and Headache Frequency in Migraine.
Study Type
Interventional

2. Study Status

Record Verification Date
March 2017
Overall Recruitment Status
Completed
Study Start Date
July 2007 (Actual)
Primary Completion Date
January 13, 2012 (Actual)
Study Completion Date
January 13, 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beth Israel Deaconess Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine whether a painless and noninvasive procedure called Transcranial Direct Current Stimulation (tDCS) can be an effective therapy for the treatment of migraine and migraine-associated pain. Stimulation of the motor cortex with tDCS has already been shown to relieve pain in patients with other chronic pain syndromes, including traumatic spinal cord injury and fibromyalgia. Patients with migraine are usually extremely sensitive to pain. A treatment that targets the areas of the brain that are related to the experience of pain may also help decrease pain in patients with migraine. Pain control with this localized approach may help avoid the problems due to pain medications that affect all organs in the body. We hypothesize that 10 sessions of Transcranial Direct Current Stimulation (tDCS) applied over the area of the brain that controls pain and motor function will decrease pain and headache frequency in patients with migraine.
Detailed Description
We will rigorously test whether modulation of the motor cortex by tDCS is an effective treatment for patients with migraine through the following specific aims: A) The primary aim of this study is to determine whether transcranial direct current stimulation applied to the motor cortex in patients with migraine induces a significant decrease in the pain associated with migraine attacks as compared with sham tDCS. We will also measure changes in the number of migraine attacks, abortive drug intake (e.g. opioids, triptans), as well as overall improvement in the quality of life to assess the effects of this treatment. B) Determine whether the clinical effects of tDCS are long-lasting. We will therefore compare the amelioration of migraine-associated pain between active and sham tDCS after 1, 2 and 4 months of treatment. C) Determine whether tDCS changes the threshold for pain detection as compared with sham tDCS. Patients with migraine have a lower threshold for pain as compared to healthy subjects and we hypothesize that this threshold as measured by Von Frey Hair Test and Quantitative Sensory Test will increase after stimulation with tDCS. D) Finally, we will examine whether 1 month of tDCS treatment is safe for use in migraine patients. Safety will be assessed through neuropsychological tests and adverse event reporting.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Migraine
Keywords
migraine, headache, chronic, pain, brain, neurology, stimulation, noninvasive, transcranial, direct, current, tDCS, tms, rTMS, BIDMC

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
13 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Baseline- 1 month
Arm Type
No Intervention
Arm Description
Subjects will be asked to maintain a migraine diary in which they will record the onset of each migraine, migraine-associated symptoms, migraine-associated pain, daily average pain, and daily average anxiety.
Arm Title
tDCS- 1 month
Arm Type
Experimental
Arm Description
There will be 10- twenty minute sessions of the tDCS intervention over a four week period. During each tDCS session, two electrodes are placed over selected areas of the brain. 2 mA of direct current will flow through the electrodes, penetrate the scalp, and create a flow of electrical current in the brain. The subject may feel a slight itching on the scalp. The procedure will last 20 minutes. For sham tDCS, an alternate method of stimulation will be used. During this phase, participants will continue to maintain their migraine diary. In addition, the pain threshold of patients will be measured at the first, fifth, and tenth sessions via Thermal Sensory Analysis and Von Frey Hair tests.
Arm Title
Follow Up- 4 months
Arm Type
No Intervention
Arm Description
During the follow up phase, subjects will meet with the study investigators a total of 5 times for follow up monitoring. Participants will continue to maintain their migraine diary during this time.
Arm Title
Active tDCS- 1 month
Arm Type
Other
Arm Description
Participants randomized to sham tDCS (placebo) will be given the opportunity to receive the active intervention if the intervention is found to be safe and efficacious.
Intervention Type
Device
Intervention Name(s)
DC Stimulator (Transcranial Direct Current Stimulator)
Other Intervention Name(s)
NeuroConn GmbH, http://www.eldith.de/products/stimulator
Intervention Description
Subjects will receive a total of 10 sessions of either active tDCS or sham tDCS over a four-week period (administered every other day during weekdays over the course of one month). During each tDCS session, two electrodes are placed over selected areas of the brain. The anode is placed on the motor cortex contralateral to the side where migraines predominant; the cathode is placed near the supraorbital area, opposite the anode. A small battery powered device drives 2 mA of direct current through the two electrodes. The direct current will flow through the electrodes, penetrate the scalp, and create a flow of electrical current in the brain. The procedure will last 20 minutes. For sham tDCS, an alternate method of stimulation will be used.
Primary Outcome Measure Information:
Title
Migraine-associated pain (maximum headache intensity)
Time Frame
6 months
Title
Migraine frequency (# of headache days per month)
Time Frame
6 months
Title
Daily average pain
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Thermal pain threshold
Time Frame
1 month
Title
Daily average anxiety
Time Frame
6 months
Title
Analgesic drug use
Time Frame
6 months
Title
Von Frey Hair
Time Frame
1 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects must be between 18 and 65 years of age. The diagnosis must meet the 2004 IHS criteria for migraine without aura, migraine with aura, or chronic migraine. The duration of the disease must be of at least one year. Subjects must have maintained their routine preventative medication consistently for at least two months (if applicable) prior to study initiation. Exclusion Criteria: Patients with major depression with suicidal risk, as clinically defined. Patients with other known neuropsychiatric disorders. Patients with other chronic pain disorders History of substance abuse or dependence within the last six months Known brain metastasis History of neurological disorders (such as stroke) History of brain surgery Prior experience with tDCS Abnormal neurological examination, other than those pertaining to the signs of the condition studied in this protocol. Contraindication to tDCS: metallic hardware in the head or scalp: shrapnel, surgical clips, or fragments from welding
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Felipe Fregni, MD, PhD
Organizational Affiliation
Berenson-Allen Center for Noninvasive Brain Stimulation; Beth Israel Deaconess Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Soroush Zaghi, B.S.
Organizational Affiliation
Harvard Medical School; Beth Israel Deaconess Medical Center
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Alexandre DaSilva, DDS, DMedSc
Organizational Affiliation
Mclean Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Beth Israel Deaconess Medical Center: Berenson-Allen Center for Noninvasive Brain Stimulation
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
17611487
Citation
Fregni F, Pascual-Leone A. Technology insight: noninvasive brain stimulation in neurology-perspectives on the therapeutic potential of rTMS and tDCS. Nat Clin Pract Neurol. 2007 Jul;3(7):383-93. doi: 10.1038/ncpneuro0530.
Results Reference
background
PubMed Identifier
17239806
Citation
Fregni F, Freedman S, Pascual-Leone A. Recent advances in the treatment of chronic pain with non-invasive brain stimulation techniques. Lancet Neurol. 2007 Feb;6(2):188-91. doi: 10.1016/S1474-4422(07)70032-7.
Results Reference
background
PubMed Identifier
17133529
Citation
Fregni F, Gimenes R, Valle AC, Ferreira MJ, Rocha RR, Natalle L, Bravo R, Rigonatti SP, Freedman SD, Nitsche MA, Pascual-Leone A, Boggio PS. A randomized, sham-controlled, proof of principle study of transcranial direct current stimulation for the treatment of pain in fibromyalgia. Arthritis Rheum. 2006 Dec;54(12):3988-98. doi: 10.1002/art.22195.
Results Reference
background
PubMed Identifier
16564618
Citation
Fregni F, Boggio PS, Lima MC, Ferreira MJ, Wagner T, Rigonatti SP, Castro AW, Souza DR, Riberto M, Freedman SD, Nitsche MA, Pascual-Leone A. A sham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury. Pain. 2006 May;122(1-2):197-209. doi: 10.1016/j.pain.2006.02.023. Epub 2006 Mar 27.
Results Reference
background
PubMed Identifier
15546593
Citation
Brighina F, Piazza A, Vitello G, Aloisio A, Palermo A, Daniele O, Fierro B. rTMS of the prefrontal cortex in the treatment of chronic migraine: a pilot study. J Neurol Sci. 2004 Dec 15;227(1):67-71. doi: 10.1016/j.jns.2004.08.008.
Results Reference
background
Links:
URL
http://tmslab.org/
Description
Related Info

Learn more about this trial

Migraine--Investigational Treatment of Migraine With Noninvasive Brain Stimulation. (tDCS- Migraine)

We'll reach out to this number within 24 hrs